KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Keros Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$11.06+0.40 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Keros Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License revenue | $10.00M | $10.00M | $205.36M | $208.36M | $198.36M | $198.36M | $3.00M | – | – | – | – | 68.8% | -95.0% |
| License revenue | $10.00M | $10.00M | $205.36M | $205.36M | $195.36M | $195.36M | $0 | – | – | – | – | 68.8% | -94.9% |
| Service and other revenue | $5.01M | $23.18M | $38.71M | $38.36M | $34.49M | $16.36M | $550.00K | $651.00K | $271.00K | $234.00K | $151.00K | 34.5% | -85.5% |
| Service revenue | $4.53M | $22.70M | $38.50M | $38.13M | $34.01M | $15.84M | $0 | – | – | – | – | 31.1% | -86.7% |
By region
From the segment and revenue-disaggregation notes of Keros Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.